Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M

SOLENO THERAPEUTICS INC

2025-Q2 EPS reported -$1.00 revenue$32,657,000

Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).
Net loss $(4.7)M or ($0.09) per share vs. $(21.9)M ($0.57) in Q2 2024.
Cash, equivalents and marketable securities $293.8M at June 30; subsequent $230M equity offering in July.
Launch metrics: 646 patient start forms, 295 unique prescribers, >100M lives covered by end of Q2.
MAA for DCCR submitted to EMA; contingent consideration liability for sales milestones estimated at $18.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.